INHIBITION OF ANTIBIOTIC-INDUCED MUTATION IN BACTERIA

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 细菌对抗菌药物的耐药性有可能成为全球健康危机。这一问题需要大量的研究来发现新的药物靶点以及合成抗生素。虽然这种策略对于保持抗生素耐药性生物体的进化至关重要，但对抗耐药性过程也很重要。细菌可以通过染色体突变获得对抗生素的抗性，并且赋予抗性的染色体突变的高比率至少部分是由于诱导修复由抗生素直接或间接引起的受损DNA的途径。与目前正在研究的其他抗菌肽不同，我们正在寻找减少细菌突变性而不是杀死细菌的肽。一旦被鉴定，这些肽可能作为抗生素添加剂，并可用于降低细菌的进化速率，而不管药物的分子靶点。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Bacterial resistance to antimicrobial drugs has the potential to become a global health crisis. This problem has necessitated an explosion of research to discover new drug targets as well as synthetic antibiotics. While this tactic is essential to stay ahead of the evolution of antibiotic resistant organisms, it is also important to combat the resistance process. Bacteria can acquire resistance to antibiotics through chromosomal mutations and high rates of resistance-conferring chromosomal mutations are at least partially due to pathways induced to repair damaged DNA caused either directly or indirectly by the antibiotic. Unlike other antimicrobial peptides currently being studied, we are looking for peptides that reduce the mutability of bacteria as opposed to killing the bacteria. Once identified, these peptides could potentially serve as antibiotic additives and could be used to reduce the evolution rate of bacteria regardless of the molecular target of the drug.